Alpha Cognition Announces Grant of Stock Options

Rhea-AI Summary

Alpha Cognition Inc. (TSX-V: ACOG, OTCQB: ACOGF) has announced the granting of stock options for directors to purchase up to 400,000 common shares at $0.64 CAD each. These options are valid for ten years, subject to vesting provisions. The company focuses on developing novel therapies for neurodegenerative disorders, notably Alzheimer's and ALS. Their lead candidate, ALPHA-1062, has shown promise in clinical trials with improved safety and tolerability. The firm is also advancing ALPHA-0602, which has received Orphan Drug Designation for treating neurodegenerative diseases.

Positive

• Granting of stock options for directors to purchase 400,000 shares at $0.64 CAD each, potentially aligning interests with shareholders.
• Development of ALPHA-1062, an innovative treatment for Alzheimer's, demonstrating safety and minimal gastrointestinal side effects in clinical trials.
• ALPHA-0602 has received Orphan Drug Designation, indicating its potential value in treating underserved neurodegenerative diseases.

Negative

• None.

VANCOUVER, British Columbia--(BUSINESS WIRE)-- Alpha Cognition Inc. (TSX-V: ACOG) (OTCQB: ACOGF) (“Alpha Cognition,” or the “Company”), a biopharmaceutical company committed to developing novel therapies with the potential to transform the lives of people with debilitating neurodegenerative disorders, announces the grant of stock options pursuant to its stock option plan to certain directors of the Company to purchase up to an aggregate of 400,000 common shares of the Company. The stock options are exercisable at a price of $0.64 CAD per share and expire ten years from the date of grant, subject to certain vesting provisions.

About Alpha Cognition Inc.

Alpha Cognition Inc. is a clinical stage, biopharmaceutical company dedicated to developing treatments for under-served neurodegenerative diseases, such as Alzheimer's Dementia and Amyotrophic Lateral Sclerosis (ALS).

ALPHA-1062, is a patented new chemical entity that has demonstrated safety and improved tolerability in human clinical trials. It is being developed as a new generation acetylcholinesterase inhibitor for the treatment of Alzheimer's disease, with minimal gastrointestinal side effects and novel routes of administration. ALPHA-1062's active metabolites are differentiated from donepezil and rivastigmine in that they may sensitize neuronal nicotinic receptors, most notably the alpha-7 subtype, which is known to have a positive effect on cognition. ALPHA-1062 is also being developed in combination with memantine to treat moderate to severe Alzheimer's dementia and in a nasal spray formulation to treat traumatic brain injury.

ALPHA-0602 (Progranulin) is expressed in several cell types in the central nervous system and in peripheral tissues, regulates cell survival and certain inflammatory processes, and plays a major role in regulating lysosomal function and microglial responses to disease. Its use for the treatment of neurodegenerative diseases has been patented by the Company and granted an Orphan Drug Designation.

Neither TSX Venture Exchange (the “TSX-V”), OTC Markets Group, nor the TSX-V’s Regulation Services Provider (as that term is defined in policies of the TSX-V) accepts responsibility for the adequacy or accuracy of this release.

View source version on businesswire.com: https://www.businesswire.com/news/home/20220531006021/en/

Bristol Investor Relations

Stefan Eftychiou

905 326 1888 ext 6

stefan@bristolir.com

https://www.alphacognition.com/

Source: Alpha Cognition Inc.

FAQ

What is the stock option grant by Alpha Cognition Inc. (ACOGF)?

Alpha Cognition Inc. has granted stock options for directors to purchase up to 400,000 common shares at a price of $0.64 CAD each, expiring in ten years, subject to vesting provisions.

What is the main focus of Alpha Cognition Inc. (ACOGF) in its drug development?

Alpha Cognition Inc. is primarily focused on developing novel therapies for neurodegenerative disorders such as Alzheimer's disease and ALS.

What is ALPHA-1062 and its significance for Alpha Cognition Inc. (ACOGF)?

ALPHA-1062 is a new candidate developed by Alpha Cognition for the treatment of Alzheimer's, showing improved safety and tolerability in clinical trials.

What is the current stock price for Alpha Cognition Inc. (ACOGF)?

The stock options are exercisable at a price of $0.64 CAD per share, as announced in the recent press release.

Has Alpha Cognition Inc. (ACOGF) received any regulatory designations for its products?

Yes, Alpha Cognition Inc. has received Orphan Drug Designation for ALPHA-0602, highlighting its potential for treating neurodegenerative diseases.